MegJardine NHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia

MegJardine
Professor Meg Jardine is the Director of the NHMRC Clinical Trials Centre, the University of Sydney and Lead of the Kidney Health Research Program. Her research has focussed on investigating the progression and complications of non-communicable diseases, particularly kidney disease and diabetes. She has experience in the design and conduct of national and international trials. Prof Jardine has a particular interest in expanding the use of innovative and cost-effective methodologies to increase the generation of high-quality evidence. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to their efficient delivery. Prof Jardine is a member of the Executive Committees of the International Society of Nephrology (ISN) and a past Board member of KDIGO. She is Chair of the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) initiative. She serves as a Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US (United States) FDA (Food and Drug Administration). She is a Board member of the Australian Clinical Trials Alliance (ACTA) and a member of the ANZSN (Australia and New Zealand Society of Nephrology) Research Advisory Committee. Prof Jardine is a specialist nephrologist at Concord Repatriation General Hospital and a proud recipient of the Australian and New Zealand Society of Nephrology T.J.Neale award for Outstanding Contribution to Nephrological Science.

Day 2 - Monday April 15, 2024

Time Session
11:00 am
12:00 pm
Jose VicenteSanchez Polo Chairperson visanpolo@gmail.comRenal Division Social Security Institute. Nephrology Residence Program Coordinator, San Carlos University School of Medicine. Latin-American Society Of Nephrology (SLANH)Guatemala
MegJardine Chairperson meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Generative AI Revolution in Medicine
    MichalRosen-Zvi Speaker ROSEN@il.ibm.comhttps://research.ibm.com/Israel
  • Acceptance Speech by Awardee (Schrier Award), with Tasnuva Sarah Kashem (UK) and Farnaz Nobi (Bangladesh)
    Mohammad Shakib Uz ZamanArefin Speaker shakib04@yahoo.comBangladesh
Hall A
12:45 pm
01:30 pm
AndreaViecelli Spotlight Speaker andrea.viecelli@health.qld.gov.auUniversity of QueenslandAustralia
Augusto CesarSoares dos Santos Junior Spotlight Speaker acssjunior@hotmail.comHospital das Clinicas, UFMG; Fac Ciências MedicasBrazil
BrendanSmyth Spotlight Speaker brendan.smyth@sydney.edu.auAustralia
DavidWheeler Spotlight Speaker d.wheeler@ucl.ac.ukUniversity College LondonUnited Kingdom
MegJardine Spotlight Chairperson meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
Spotlight Stage 1 (exhibition hall)

Day 3 - Tuesday April 16, 2024

Time Session
09:00 am
10:00 am
DebasishBanerjee Chairperson dbanerje@sgul.ac.ukSt George's University Hospital NHS Foundation TrUnited Kingdom
MegJardine Chairperson meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Setting the Scene
    MegJardine Speaker meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • DM and CKD: Which Treatment Should I Use for Different Populations?
    KatherineTuttle Speaker Katherine.Tuttle@providence.orgUniversity of Washington, Department of NephrologyUnited States
  • How to Design Studies on Answering Unanswered Questions
    VladoPerkovic Speaker vlado.perkovic@unsw.edu.auUniversity of New South Wales, Sydney, AustraliaAustralia
  • The Effect of SGLT2 Inhibitors in Patients with Chronic Kidney Disease, With or Without Type 2 Diabetes
    DavidWheeler Speaker d.wheeler@ucl.ac.ukUniversity College LondonUnited Kingdom
  • Q and A
Hall C4